FDA Approves First Treatment for Cerebral Folate Transport Deficiency
The U.S. Food and Drug Administration (FDA) has approved an expanded use of Wellcovorin (leucovorin calcium) tablets to treat patients with cerebral folate deficiency caused by variants in the folate receptor 1 gene (CFD-FOLR1). The approval applies to both adult and pediatric patients and represents the first FDA-approved treatment for this rare genetic condition.
Cerebral folate deficiency is a neurological disorder in which the body cannot properly transport folate, a vitamin essential for brain development, into the central nervous system. Patients with CFD-FOLR1 often experience severe developmental delays, seizures, movement disorders, and other neurological complications.
According to FDA Commissioner Marty Makary, M.D., M.P.H., the approval reflects the agency’s efforts to accelerate treatments for patients with serious conditions that currently lack effective therapies.
Evidence from Published Literature and Real-World Data
Unlike many drug approvals that rely primarily on large randomized clinical trials, the FDA based this decision largely on a systematic review of published scientific literature, including case reports containing patient-level clinical data and mechanistic studies explaining the drug’s biological effects.
Regulators also evaluated real-world evidence demonstrating clinical improvement in patients compared with the natural course of the disease. Acting Director of the FDA’s Center for Drug Evaluation and Research Tracy Beth Hoeg, M.D., Ph.D., noted that the approval illustrates how observational evidence can support regulatory decisions in rare diseases where traditional clinical trials may be difficult to conduct.
Regulatory Collaboration
The FDA worked with GSK, the holder of the New Drug Application (NDA) for Wellcovorin, to update the drug’s labeling with the information needed for safe and effective use in patients with CFD-FOLR1.
This type of labeling update allows an existing therapy to be formally recognized as an FDA-approved treatment for a specific rare disease indication.
Safety Information
Leucovorin is generally well understood, but potential side effects include itching (pruritus), rash and hives, breathing difficulty (dyspnea), chills or shivering (rigors), and impaired temperature regulation. In rare cases, anaphylaxis, a severe allergic reaction, may occur requiring immediate medical treatment.
Significance for Rare Disease Patients
The approval provides the first FDA-recognized therapy for individuals with CFD-FOLR1 and highlights the agency’s increasing use of flexible evidentiary approaches when evaluating treatments for ultra-rare conditions. By incorporating literature reviews, mechanistic data, and real-world clinical evidence, regulators were able to support approval for a therapy addressing a serious unmet medical need.
For more information, click the download box in the right column of this post to review the supplemental approval document and click here to see the FDA announcement.
Download the GSK Supplemental Approval Letter
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...